ArticleTranslational lung cancer research2026
Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Targeting KRASFrontiers in oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Background: Methods: HER2 expression in 11 xenograft models and in 191 clinical and autopsy samples from 31 patients with advanced-stage NSCLC was assessed using breast cancer (BC) and gastroesophageal adenocarcinoma (GEA) HER2 immunohistochemistry (IHC) interpretation guidelines. Responses to sotorasib, T-DXd, and their combination were evaluated in therapy-naïve and sotorasib-relapsed (SR) xenografts. Results: The sotorasib-T-DXd combination induced deeper and more durable tumor regressions than either monotherapy, including in SR xenograft models. Enhanced activity was associated with sotorasib-induced adaptive HER2 upregulation, with stronger HER2 expression in SR tumors correlating with greater responses. In patient samples, HER2 expression was more frequent in Conclusions: Sotorasib plus T-DXd produced durable regressions in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.